ŚLIWA, Natalia, DĄDELA, Bartosz, KAWALSKA, Eliza, MAJEWSKA, Emilia, GNITECKI, Szymon, BOROWSKI, Maciej, JANCZURA, Szymon, ZIELONKA, Kacper, MARKOWSKI, Marcin and JASIŃSKA, Joanna. Statin Intolerance and Adverse Effects in Lipid-Lowering Therapy – Pathomechanisms, Management Strategies, and Alternative Treatment Approaches. Quality in Sport. 2025;42:61202. eISSN 2450-3118.
https://doi.org/10.12775/QS.2025.42.61202
https://apcz.umk.pl/QS/article/view/61202

The journal has been awarded 20 points in the parametric evaluation by the Ministry of Higher Education and Science of Poland. This is according to the Annex to the announcement of the Minister of Higher Education and Science dated 05.01.2024, No. 32553. The journal has a Unique Identifier: 201398. Scientific disciplines assigned: Economics and Finance (Field of Social Sciences); Management and Quality Sciences (Field of Social Sciences).
Punkty Ministerialne z 2019 - aktualny rok 20 punktów. Załącznik do komunikatu Ministra Szkolnictwa Wyższego i Nauki z dnia 05.01.2024 Lp. 32553. Posiada Unikatowy Identyfikator Czasopisma: 201398. Przypisane dyscypliny naukowe: Ekonomia i finanse (Dziedzina nauk społecznych); Nauki o zarządzaniu i jakości (Dziedzina nauk społecznych).
The authors declare that there is no conflict of interest regarding the publication of this paper.
Received: 19.05.2025. Revised: 25.06.2025. Accepted: 25.06.2025. Published: 27.06.2025.

Statin Intolerance and Adverse Effects in Lipid-Lowering Therapy – Pathomechanisms, Management Strategies, and Alternative Treatment Approaches

Natalia Śliwa

Maria Skłodowska-Curie Provincial Specialist Hospital in Zgierz,

ul. Parzęczewska 35, 95-100 Zgierz, Poland

https://orcid.org/0009-0000-9829-1915

sliwanatalia1998@gmail.com

Bartosz Dądela

Maria Skłodowska-Curie Provincial Specialist Hospital in Zgierz,

ul. Parzęczewska 35, 95-100 Zgierz, Poland

https://orcid.org/0009-0003-2408-9812

bartoszdadela33@gmail.com

Eliza Kawalska

Hospital of Our Lady of Perpetual Help in Wołomin,

ul. Gdyńska 1/3, 05-200 Wołomin, Poland

https://orcid.org/0009-0004-8244-6459

ekawalska98@gmail.com

Emilia Majewska

Dr. Tytus Chałubiński Specialist Hospital in Radom,

ul. Adolfa Tochtermana 1, 26-610 Radom, Poland

https://orcid.org/0009-0009-3043-1104
emiliamajewska98@gmail.com

Szymon Gnitecki

Provincial Multi-Specialist Center of Oncology and Traumatology M. Copernicus in Łódź,

ul. Pabianicka 62, 93-513 Łódź.

https://orcid.org/0009-0007-6839-6207

szymciog9@gmail.com

Maciej Borowski

Central Clinical Hospital of Medical University of Lodz,

ul. Pomorska 251, 92-213 Łódź, Poland

maciej.piotr.borowski@gmail.com
https://orcid.org/0009-0001-0789-804X

Szymon Janczura

Central Clinical Hospital of Medical University of Lodz,

ul. Pomorska 251, 92-213 Łódź, Poland

https://orcid.org/0009-0009-4214-4014

janczura.szymon@gmail.com

Kacper Zielonka

Maria Skłodowska-Curie Provincial Specialist Hospital in Zgierz,

ul. Parzęczewska 35, 95-100 Zgierz, Poland

https://orcid.org/0009-0009-5149-7786

kzielonka09@gmail.com

Marcin Markowski

Medical University of Łódź,

al. Kościuszki 4, 90-419, Łódź, Poland

https://orcid.org/0009-0006-5497-1138

ma.markowski98@gmail.com

Joanna Jasińska

Central Clinical Hospital of Medical University of Lodz,

ul. Pomorska 251, 92-213 Łódź, Poland

https://orcid.org/0009-0008-2496-1355

jojasinska99@gmail.com

Abstract

Statins are essential in preventing cardiovascular diseases by lowering LDL cholesterol levels. Landmark trials like 4S and HPS demonstrated significant reductions in cardiovascular events and mortality with statin use. Statins inhibit hepatic cholesterol synthesis and upregulate LDL receptors, improving endothelial function and exerting anti-inflammatory effects. However, adverse effects can lead to discontinuation. Musculoskeletal symptoms, including myalgia and rhabdomyolysis, affect 5-20% of patients, often linked to mitochondrial dysfunction and coenzyme Q10 depletion. Hepatotoxicity, although less frequent, presents as elevated transaminases, particularly with lipophilic statins. Statins may also increase new-onset diabetes risk by 9-12%, potentially due to impaired insulin signaling and mitochondrial dysfunction. Cognitive effects remain controversial, with some reports of memory impairment, especially with lipophilic statins. Managing statin intolerance involves dose reduction, switching to hydrophilic statins, or coenzyme Q10 supplementation. Alternative therapies for statin-intolerant patients include ezetimibe, PCSK9 inhibitors, and bempedoic acid. Lifestyle interventions like a Mediterranean diet and regular exercise further support cardiovascular health while minimizing adverse effects.

Keywords: statins, HMG-CoA, Myopathy, liver disease, cholesterol, PCSK9

Introduction

Statins, representing a class of pharmaceutical agents that competitively inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, have established themselves as the pharmacological foundation for both primary and secondary prevention of cardiovascular diseases (Endo, 2010). Since their introduction in the late 20th century, these compounds have revolutionized the management of dyslipidemia, demonstrating unparalleled efficacy in reducing plasma concentrations of low-density lipoprotein cholesterol (LDL-C) by 30-60% depending on the specific agent and dosage employed (Cholesterol Treatment Trialists' Collaboration et al., 2015; Mach et al., 2020). The clinical benefits of statin therapy are well-substantiated by an extensive body of evidence from landmark clinical trials including the Scandinavian Simvastatin Survival Study (4S) (Scandinavian Simvastatin Survival Study Group, 1994), Heart Protection Study (HPS) (Heart Protection Study Collaborative Group, 2002), and Cholesterol Treatment Trialists' (CTT) Collaboration meta-analyses (Cholesterol Treatment Trialists' Collaboration et al., 2019), which collectively demonstrate significant reductions in major adverse cardiovascular events (20-40%), cardiovascular mortality (15-30%), and all-cause mortality (10-15%) across diverse patient populations (Arnett et al., 2019).

The therapeutic success of statins stems from their dual mechanism of action: direct inhibition of hepatic cholesterol biosynthesis and subsequent upregulation of LDL receptor expression (Grundy et al., 2018). By blocking the rate-limiting step in the mevalonate pathway, statins not only reduce intracellular cholesterol production (Libby et al., 2021) but also deplete isoprenoid intermediates such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate, which are critical for the post-translational modification of various signaling proteins (Stroes et al., 2015). This unique pharmacological profile accounts for both their cholesterol-lowering effects (Banach et al., 2018) and their pleiotropic benefits, including improved endothelial function (Libby, Aikawa., 2003), stabilization of atherosclerotic plaques (Libby, 2021), and anti-inflammatory properties mediated through reduced C-reactive protein levels (Ridker et al., 2017).

Despite these well-documented cardiovascular benefits, statin therapy is frequently complicated by a spectrum of adverse effects that collectively represent one of the most common causes of treatment discontinuation in clinical practice (Zhang et al., 2013). Musculoskeletal complications, ranging from benign myalgia (5-20% prevalence) to severe rhabdomyolysis (<0.1% incidence) (Mancini et al., 2016), constitute the most frequently reported adverse events, with pathogenesis linked to mitochondrial dysfunction , depletion of coenzyme Q10 , and impaired

selenoprotein synthesis (Qu et al., 2018). Hepatotoxicity, manifesting as asymptomatic transaminase elevations (1-3% of patients) or rarely as clinically apparent liver injury (Björnsson et al., 2017), represents another significant concern, particularly with lipophilic statins that undergo extensive hepatic metabolism (Bhardwaj et al., 2007). The diabetogenic potential of statins has emerged as a particularly controversial issue, with meta-analyses indicating a 9-12% increased risk of new-onset diabetes mellitus (Sattar et al., 2016; Cederberg et al., 2015), likely mediated through β-cell dysfunction (Preiss et al., 2016) and peripheral insulin resistance (Koh et al., 2013). Additional concerns include potential neurocognitive effects (Rojas-Fernandez, Cameron., 2014), though the evidence remains inconclusive, with some studies suggesting subtle memory impairment (Wagstaff et al., 2003) while others show no significant association.

The interindividual variability in statin tolerance appears to be influenced by multiple factors, including genetic polymorphisms (notably SLCO1B1 variants affecting hepatic uptake) (Mangravite et al., 2013), concomitant medications (particularly CYP3A4 inhibitors) (Neuvonen et al., 1998), and patient characteristics such as advanced age, low body mass index (Turner et al., 2020). This complex interplay of pharmacological and host factors underscores the importance of personalized approaches to statin therapy (Stroes et al., 2015; Mach et al., 2020), balancing cardiovascular risk reduction against potential adverse effects (Brown et al., 2020).

Aim of study

This comprehensive review aims to systematically analyze the pathomechanisms underlying statin intolerance, with particular focus on musculoskeletal, metabolic, hepatic and neurocognitive adverse effects, while evaluating evidence-based management strategies including dose adjustment, alternate statin selection and intermittent dosing regimens. The study further assesses the efficacy and safety profile of alternative lipid-lowering therapies such as PCSK9 inhibitors, ezetimibe and bempedoic acid in statin-intolerant populations, based on recent clinical trial data and current guideline recommendations. Additionally, the review explores emerging personalized approaches including pharmacogenomic testing and novel therapeutic agents that may optimize cardiovascular risk reduction while minimizing adverse effects in high-risk patients who cannot tolerate conventional statin therapy. The synthesis of current evidence aims to provide clinicians with practical strategies for managing statin intolerance while maintaining effective cardiovascular protection.

Benefits and Risks of Statin Therapy

Statins have been the cornerstone of modern cardiology and cardiovascular disease prevention for decades, providing measurable benefits in reducing the risk of heart attacks, strokes, and cardiac-related deaths (Cholesterol Treatment Trialists, 2010; Cholesterol Treatment Trialists, 2019). The Cholesterol Treatment Trialists' Collaboration meta-analysis, encompassing data from 170,000 patients, clearly demonstrated that each 1 mmol/L reduction in LDL cholesterol translates to a 22% decrease in major coronary events, 16% lower risk of stroke, and 10% reduction in overall mortality (Cholesterol Treatment Trialists, 2010). Particularly significant benefits are observed in patients with previous cardiovascular events, where statin therapy reduces the risk of subsequent events by 25-30%, while in primary prevention for high-risk individuals this effect reaches 20-25% (Cholesterol Treatment Trialists' Collaboration, 2012).

Despite these undeniable benefits, statin therapy is associated with a spectrum of adverse effects that require careful therapeutic consideration. Muscle-related symptoms are the most common, affecting 5-10% of patients, while severe rhabdomyolysis occurs rarely, in less than 0.1% of cases (Stroes et al.,2015; Rosenson et al., 2012). The mechanism of these complications is primarily related to the inhibition of coenzyme Q10 synthesis and mitochondrial dysfunction, as confirmed by both clinical and experimental studies (Schirris et al., Skarlovnik

2014). Another significant adverse effect is a 9-12% increased risk of developing type 2 diabetes, particularly in individuals with existing risk factors such as obesity or prediabetes (Sattar et al., 2010; Ridker et al., 2008).

The benefit-risk balance varies significantly depending on patient subgroups. In populations requiring secondary prevention, the cardiovascular benefits clearly outweigh potential risks, as confirmed by landmark studies such as 4S (Scandinavian Simvastatin Survival Study Group, Lancet 1994) and CARE (Sacks et al., N Engl J Med 1996). For primary prevention, current guidelines emphasize the importance of individualized approaches based on quantitative risk assessment (Grundy et al., 2018), with particular attention to intermediate-risk patients where absolute benefits may be limited (Yebyo et al., 2019).

Myopathy during statin therapy

Despite statins proven benefits, a notable side effect of statin therapy is the development of muscle-related symptoms, collectively referred to as statin-associated muscle symptoms (SAMS). These can range from mild muscle pain (myalgia) to severe, potentially life-threatening conditions like rhabdomyolysis. Studies suggest that 5-10% of patients experience some form of muscle discomfort during statin treatment, while more severe myopathy occurs in less than 0.1% of cases (Thompson et al., 2016).

The exact mechanisms behind statin-induced myopathy are not fully understood, but several key factors contribute to its development. One proposed mechanism involves mitochondrial dysfunction. Statins reduce the production of coenzyme Q10 (CoQ10), a critical component of the mitochondrial electron transport chain, which may impair energy production in muscle cells and lead to fatigue and damage (Stroes et al., 2015). Another potential mechanism is disruption of calcium signaling in muscle cells. Statins may interfere with sarcoplasmic reticulum function, leading to abnormal calcium release and contributing to muscle injury (Sirvent et al., 2012). Additionally, genetic factors play a role, particularly variations in the SLCO1B1 gene, which affects statin metabolism and increases the risk of muscle toxicity (Link et al., 2008).

Certain individuals are at a higher risk of developing statin-related myopathy. Older adults, particularly those over 75, are more susceptible due to age-related declines in muscle mass and kidney function. Patients with low vitamin D levels also face an increased risk, as vitamin D deficiency is associated with muscle weakness and may exacerbate statin-induced damage (Michalska-Kasiczak et al., 2018). Other risk factors include high statin doses, concomitant use of interacting medications (such as fibrates or certain antibiotics), and pre-existing muscle disorders. Women may also be more prone to statin myopathy than men, though the reasons for this disparity remain unclear.

To minimize the risk of myopathy during statin therapy, several preventive strategies can be employed. Starting with a low to moderate statin dose and gradually increasing it, if necessary, may help reduce muscle-related side effects. Monitoring vitamin D levels and supplementing if deficient could also lower the likelihood of muscle symptoms. Some studies suggest that coenzyme Q10 supplementation might alleviate statin-induced myopathy, though evidence remains inconclusive (Skarlovnik et al., 2014). Patients should also be advised to avoid excessive alcohol consumption and vigorous exercise when initiating statin therapy, as these factors may worsen muscle injury.

For high-risk patients, recommended approaches include initiating therapy with lower doses of safer statins (e.g., pravastatin 20-40 mg/day or rosuvastatin 5-10 mg/day) (Mancini et al., 2016), avoiding simvastatin doses >20 mg/day in elderly patients (SEARCH Collaborative Group, 2010). Regular monitoring should include creatine kinase levels (Parker et al., 2013), vitamin D status (Michos et al., 2017), and renal function (Wanner et al., 2013), with vitamin D supplementation when deficient (Michalska-Kasiczak et al., 2018).

For patients developing muscle symptoms, temporary statin withdrawal (2-4 weeks) followed by rechallenge with a different statin at reduced dose or intermittent dosing may be considered (Stroes et al., 2015). Persistent

intolerance may require alternative lipid-lowering agents like ezetimibe (Kosoglou et al., 2005), PCSK9 inhibitors (Sabatine et al., 2017), or bempedoic acid (Laufs et al., 2019).

Statin-Induced Liver Injury

The use of statins is associated with potential hepatotoxicity, which remains a significant concern for clinicians. The incidence of statin-related liver injury follows a characteristic bimodal distribution, with mild asymptomatic transaminase elevations occurring in 1% of patients within the first 4-12 weeks of therapy (Stone et al., 2014), while idiosyncratic hepatotoxicity is much rarer, affecting fewer than 1 in 10,000 patients (Björnsson, 2017). The mechanisms underlying statin hepatotoxicity are multifactorial, involving both dose-dependent and idiosyncratic pathways (Bhardwaj, Chalsani., 2007).

At the cellular level, statins exert their hepatotoxic effects primarily through mitochondrial dysfunction, as demonstrated in multiple in vitro and animal studies (Schirris et al., 2015). By inhibiting the mevalonate pathway, statins reduce production of not only cholesterol but also several important isoprenoid intermediates, including coenzyme Q10 (Deichmann et al., 2010; Marcoff , Thompson, 2007). This leads to impaired electron transport chain function and increased oxidative stress within hepatocytes (Schirris et al., 2015). The resulting mitochondrial damage triggers apoptosis through activation of the mitochondrial permeability transition pore (Nassir et al., 2015). Additionally, statins may interfere with hepatocyte membrane stability by altering cholesterol content, further contributing to cellular injury (Björnsson et al., 2017).

The risk of hepatotoxicity varies significantly among different statins, largely due to differences in their pharmacokinetic properties (Law, Rudnicka, 2006). Lipophilic statins such as simvastatin and atorvastatin demonstrate greater hepatocyte penetration and consequently higher potential for liver injury compared to more hydrophilic agents like pravastatin and rosuvastatin (Bitzur et al., 2013). This differential risk was clearly demonstrated in the PRIMO study (Bruckert et al., 2005), which prospectively evaluated over 7,900 patients. Furthermore, statins metabolized through the CYP3A4 pathway (simvastatin, lovastatin, atorvastatin) are particularly susceptible to drug-drug interactions that can increase hepatotoxicity risk when co-administered with strong CYP3A4 inhibitors such as macrolide antibiotics or antifungal agents (Sakaeda et al., 2013).

Several patient-specific factors significantly influence hepatotoxicity risk, as highlighted in recent guidelines from the American College of Cardiology (Grundy et al., 2018). Advanced age (>65 years) and female sex are associated with increased susceptibility, likely due to altered drug metabolism and distribution (Schachter, 2005). Underlying liver conditions represent particularly important risk factors - patients with non-alcoholic fatty liver disease (NAFLD) may experience worsening steatosis (Sigler et al., 2018), while those with advanced cirrhosis (Child-Pugh B or C) are generally not candidates for statin therapy due to impaired drug clearance (Alexander, 2019). Genetic polymorphisms, particularly in the SLCO1B1 and CYP3A4 genes, can also substantially modify individual risk profiles, as demonstrated in the SEARCH collaborative genome-wide association study (Link et al., 2008).

Clinical management of statin-related hepatotoxicity requires a balanced approach, as outlined in recent expert consensus statements . Baseline liver function testing is essential before initiating therapy, with follow-up monitoring recommended at 4-12 weeks, particularly in high-risk patients (Grundy et al., 2018). For patients who develop transaminase elevations >3× ULN, temporary discontinuation with subsequent rechallenge at a reduced dose or with an alternative statin is often successful (Grundy et al., 2018). In cases where statin intolerance persists, alternative lipid-lowering strategies including ezetimibe (Cannon et al., 2015), PCSK9 inhibitors (Sabatine et al., 2017), or bempedoic acid (Laufs et al., 2019) may be considered, as recommended in the 2022 ACC Expert Consensus Decision Pathway (Lloyd-Jones et al., 2022).

Emerging research suggests potential protective strategies against statin hepatotoxicity. Coenzyme Q10 supplementation has shown promise in mitigating mitochondrial dysfunction in several small clinical trials (Skarlovnik et al., 2014), though larger randomized controlled trials are needed (Banach et al., 2015). Additionally,

novel statin formulations with reduced systemic bioavailability and hepatoselective delivery systems are under investigation to minimize liver exposure while maintaining therapeutic efficacy (Averbukch et al., 2022). Recent advances in pharmacogenomics also offer promise for personalized statin therapy to minimize hepatotoxicity risk (Cooper-DeHoff et al., 2022).

Statins, the cornerstone of cardiovascular prevention, have demonstrated unparalleled efficacy in reducing atherosclerotic cardiovascular disease events. However, their widespread use has uncovered important metabolic consequences that warrant careful consideration in clinical practice(Cholesterol Treatment Trialists' Collaboration, 2019). The relationship between statin therapy and glucose metabolism disturbances was first brought to light by the JUPITER trial in 2008, which revealed a 27% increased risk of new-onset diabetes with rosuvastatin treatment (Ridker et al., 2008). Subsequent meta-analyses have consistently shown that statin therapy is associated with a 9-12% increased risk of developing type 2 diabetes, with this effect being dose-dependent and varying among different statins (Sattar et al., 2010; Preiss et al., 2011).

Metabolic Consequences of Statin Therapy

The pathophysiological mechanisms underlying statin-induced glucose metabolism disturbances are multifaceted. By inhibiting HMG-CoA reductase, statins reduce the production of isoprenoid intermediates that are crucial for normal insulin signaling pathways (Banach et al., 2015). Experimental studies have demonstrated that statins impair glucose transporter 4 (GLUT4) translocation to the cell membrane in adipocytes and skeletal muscle cells, thereby reducing insulin-mediated glucose uptake (Koh et al., 2013). Furthermore, statins may induce endoplasmic reticulum stress in pancreatic β-cells, leading to impaired insulin secretion (Laybutt et al., 2007). Additionally, mitochondrial dysfunction in adipocytes – another consequence of statin therapy – contributes to systemic insulin resistance by reducing adiponektyn secretion and impairing insulin sensitivity (Wang et al., 2013). Genetic studies have provided compelling evidence for a causal relationship, showing that polymorphisms in the HMGCR gene are associated with increased diabetes risk (Swerdlow et al., 2015).

The diabetogenic effect of statins exhibits significant interindividual variability. Advanced age (>65 years), obesity (BMI >30 kg/m²), prediabetes, and metabolic syndrome markedly increase susceptibility to statin-induced glucose metabolism disturbances (Cederberg et al., 2015). Importantly, not all statins affect glucose metabolism equally. Comparative analyses indicate that pravastatin and pitavastatin appear metabolically neutral or even potentially beneficial, while high-potency statins like rosuvastatin and atorvastatin demonstrate more pronounced effects on glycemic parameters (Navarese et al., 2015).

Clinical management of statin-related metabolic effects requires a balanced approach. The American Diabetes Association (2022) recommends regular monitoring of fasting glucose and HbA1c in high-risk patients, with particular attention to those receiving high-intensity statin therapy (American Diabetes Association Professional Practice Committee, 2022). When metabolic disturbances occur, clinicians should consider switching to metabolically neutral statins rather than discontinuing therapy, given the overwhelming cardiovascular benefits that generally outweigh the modest increase in diabetes risk (Cholesterol Treatment Trialists' Collaboration, 2019). Lifestyle interventions, including weight loss and increased physical activity, remain crucial for mitigating metabolic risk factors in statin-treated patients.

Cognitive Issues in Statin Therapy

The impact of statins on cognitive function remains one of the most controversial aspects of cardiovascular pharmacotherapy (Schultz et al., 2018). Since their introduction in the 1980s, reports of their potential effects on

memory processes and executive functions have sparked lively debate in the medical community(Rojas-Fernandez, Cameron., 2012). In 2012, the U.S. Food and Drug Administration (FDA) issued a warning about possible transient memory impairment in patients taking statins, significantly influencing perceptions of these drugs' safety (FDA, 2012). Despite numerous studies conducted in subsequent years, the relationship between statin use and cognitive impairment remains incompletely understood, with results often being contradictory.

The molecular mechanisms underlying statins' potential cognitive effects are complex and multifactorial. Cholesterol in the brain plays a crucial role in synapse formation, memory processes, and maintaining proper neuronal membrane structure (Pfrieger ,Ungerer, 2011). By inhibiting HMG-CoA reductase, statins reduce cholesterol synthesis not only in the liver but also in the central nervous system, potentially disrupting interneuronal signaling (Pfrieger ,Ungerer, 2011). This effect appears particularly significant for lipophilic statins such as simvastatin and atorvastatin, which readily cross the blood-brain barrier (Johnson-Anuna et al., 2005).

Another important mechanism involves statins' effects on mitochondrial function in nerve cells. Statins reduce the availability of coenzyme Q10, which plays a key role in the mitochondrial respiratory chain (Deichman et al., 2010). Consequently, ATP production decreases, particularly affecting neurons, which have high energy demands (Mollazadeh et al ., 2021 ;Schrris et al., 2015). In vitro studies have demonstrated that statin exposure leads to increased reactive oxygen species production and oxidative stress in neurons, potentially accelerating neurodegenerative processes (Mollazadeh et al ., 2021 ;Schrris et al., 2015). These observations may explain reports of "brain fog" described by some statin users.

Clinical reports on statin-associated cognitive impairment remain inconsistent. On one hand, randomized controlled trials such as the PROSPER study in elderly populations showed no significant cognitive effects of pravastatin (Shepherd et al., 2002).

In clinical practice, various forms of statin-associated cognitive impairment have been observed. The most commonly reported are subjective complaints such as concentration difficulties, word-finding problems, and general slowing of thought processes (Wagstaff et al., 2003; Rojas-Fernandez, Cameron, 2012). More severe disturbances like transient global amnesia—characterized by sudden-onset short-term memory impairment with preserved remote memory—occur much less frequently (Healy et al., 2009). Most evidence suggests these symptoms are reversible upon discontinuation, though full cognitive recovery may take several months in some cases.

Risk factors for statin-associated cognitive impairment include advanced age (over 75 years), presence of the APOE ε4 allele associated with Alzheimer's disease, and concurrent kidney or liver dysfunction (Johnson-Anuna et al., 2005). Research shows APOE ε4 carriers have increased blood-brain barrier permeability to statins, potentially explaining their greater susceptibility to adverse effects (Johnson-Anuna et al., 2005). Additionally, some studies suggest women may be more vulnerable to statin-related cognitive effects than men, though the mechanisms remain unclear (Schultz et al., 2018).

Managing patients reporting cognitive symptoms during statin therapy requires a stepwise approach. First, alternative causes such as depression, vitamin deficiencies (e.g., B12), or neurodegenerative diseases should be ruled out (Swiger et al., 2013). When a temporal relationship between statin initiation and symptom onset is confirmed, switching to hydrophilic statins (e.g., pravastatin or rosuvastatin) or dose reduction may be considered (Rojas-Fernandez, Cameron, 2012). In some cases, complete statin discontinuation for 2-3 months may be necessary to assess symptom resolution, with alternative cholesterol-lowering therapies like ezetimibe or PCSK9 inhibitors as potential options (Cheeley et al., 2022).

Recent years have seen emerging evidence for coenzyme Q10 supplementation in preventing statin-associated cognitive effects (Rundek et al., 2004; Skarlovnik et al., 2014). While results are inconsistent, some studies suggest 100-200 mg daily may reduce symptoms in susceptible patients. Similarly, Mediterranean diets rich in antioxidants may counteract statins' potential negative cognitive impacts (Martínez-Lapiscina et al., 2012).

Future directions include developing next-generation statins with limited CNS activity and personalized approaches based on genetic profiling (McFarland et al., 2021). Particularly promising are studies on

polymorphisms in statin metabolism-related genes that could identify high-risk individuals (Licher et al., 2022). Concurrently, intensive research continues into statins' potential neuroprotective effects in neurodegenerative diseases like Alzheimer's, further complicating our understanding of these drugs' cognitive impacts (Schultz et al**.,** 2018)**.**

Therapeutic Alternatives for Statin-Intolerant Patients

For patients experiencing statin intolerance, treatment modification represents a viable first approach. Clinical evidence suggests that many patients can successfully resume therapy after a drug holiday, particularly with reduced doses or hydrophilic statins like pravastatin or rosuvastatin (Rojas-Fernandez, Cameron,. 2014). The SAMSON trial demonstrated that approximately 50% of patients reporting muscle symptoms could continue statin therapy with proper dose adjustment (Howard et al., 2021).

When modified statin regimens remain intolerable, alternative lipid-lowering agents should be considered. Ezetimibe, a cholesterol absorption inhibitor, serves as a primary alternative, reducing LDL-C by 15-20% as monotherapy (Cannon et al., 2015). The IMPROVE-IT trial established that adding ezetimibe to simvastatin provides additional cardiovascular benefit in post-ACS patients (Cannon et al., 2015).

Bile acid sequestrants, including newer agents like colesevelam, offer another therapeutic option. While gastrointestinal side effects may limit their use, colesevelam demonstrates improved tolerability and modest glucose-lowering effects beneficial for diabetic patients (Brunetti, Hermes-DeSantis., 2010).

PCSK9 inhibitors have revolutionized treatment for statin-intolerant patients. These monoclonal antibodies, administered via subcutaneous injection, achieve 50-60% LDL-C reduction with excellent safety profiles (Sabatine et al., 2017). The FOURIER and ODYSSEY outcomes trials confirmed their cardiovascular benefits (Sabatine et al., 2017; Schwartz et al., 2018).Bempedoic acid, approved in 2020, inhibits hepatic ATP-citrate lyase to reduce cholesterol synthesis. As monotherapy, it lowers LDL-C by 15-20%, with effects reaching 35-40% when combined with ezetimibe. The CLEAR Outcomes trial demonstrated its potential cardiovascular benefits (Goldberg et al., 2019).For severe familial hypercholesterolemia, lomitapide or MTP inhibitors may be considered. Lomitapide reduces LDL-C by 40-50% in homozygous FH but requires careful monitoring (Cuchel et al., 2013). Non-pharmacologic approaches remain essential components of management. Mediterranean diets, regular exercise, and weight loss significantly improve lipid profiles (Estruch et al., 2018). Treatment selection should be individualized based on intolerance severity and cardiovascular risk. Emerging therapies like ANGPTL3 inhibitors (evinacumab) and gene therapies show promise for future management (Rall et al., 2020). Current guidelines emphasize structured approaches to statin intolerance management (Grundy et al., 2018).

Summary

Statin therapy remains the gold standard for cardiovascular prevention, demonstrating robust efficacy in reducing LDL cholesterol by 30-60% and significantly lowering cardiovascular events and mortality. These benefits stem from their dual mechanism of inhibiting hepatic cholesterol synthesis while upregulating LDL receptor expression, complemented by pleiotropic effects including improved endothelial function and plaque stabilization. However, statin use is frequently complicated by adverse effects that challenge treatment adherence. Musculoskeletal symptoms affect 5-20% of patients, ranging from mild myalgia to rare but severe rhabdomyolysis, with mechanisms involving mitochondrial dysfunction and CoQ10 depletion. Hepatotoxicity manifests in 1-3% as transient transaminase elevations, while more concerning is the 9-12% increased diabetes risk, particularly with high-potency statins in predisposed individuals. Cognitive effects remain controversial, with some reports of transient memory impairment contrasting with potential neuroprotective benefits.The management of statin intolerance requires personalized approaches. For muscle symptoms, strategies include dose reduction, switching to alternative statins (particularly hydrophilic agents like pravastatin or rosuvastatin), or intermittent dosing regimens. Emerging evidence supports CoQ10 supplementation, though its benefits require further confirmation. Hepatotoxicity management emphasizes baseline and periodic liver function monitoring, with statin

discontinuation only for persistent transaminase elevations exceeding 3×ULN. The diabetes risk, while real, should be contextualized against statins' overwhelming cardiovascular benefits, particularly in high-risk patients, with monitoring recommended for those with metabolic risk factors.For truly statin-intolerant patients, alternative therapies have expanded significantly. Ezetimibe provides modest LDL reduction (15-20%) with excellent tolerability, while PCSK9 inhibitors offer potent 50-60% LDL lowering with proven cardiovascular outcomes benefits. Bempedoic acid presents a novel oral option targeting hepatic cholesterol synthesis without muscle effects, and bile acid sequestrants remain useful despite gastrointestinal side effects. Future directions include pharmacogenomic approaches to identify high-risk patients and novel agents like ANGPTL3 inhibitors. Importantly, lifestyle interventions maintain foundational importance, with Mediterranean diets and exercise providing complementary benefits. Current guidelines emphasize that cardiovascular risk reduction should remain the priority, with statin intolerance requiring careful diagnosis rather than automatic discontinuation, as many patients can tolerate modified regimens after appropriate rechallenge. The evolving landscape continues to balance these agents' proven benefits against their manageable risks through individualized therapeutic strategies.

Discloure

Author's Contributions Statement

Conceptualization: Bartosz Dądela, Natalia Śliwa, Szymon Janczura

Methodology: Eliza Kawalska, Joanna Jasińska, Bartosz Dądela, Szymon Gnitecki

Software: Szymon Janczura, Emilia Majewska, Maciej Borowski, Kacper Szymon Zielonka

Check: Kacper Zielonka, Marcin Markowski, Emilia Majewska, Maciej Borowski

Formal analysis: Natalia Śliwa, Joanna Jasińska, Bartosz Dądela, Szymon Gnitecki

Investigation: Bartosz Dądela, Marcin Markowski, Eliza Kawalska, Szymon Janczura

Resources: Kacper Zielonka, Bartosz Dądela, Marcin Markowski, Szymon Gnitecki

Data curation: Bartosz Dądela, Marcin Markowski, Natalia Śliwa, Eliza Kawalska

Writing – rough preparation: Kacper Szymon Zielonka, Joanna Jasińska, Bartosz Dądela, Marcin Markowski, Natalia Śliwa, Emilia Majewska, Eliza Kawalska, Szymon Gnitecki, Szymon Janczura, Maciej Borowski

Writing – review and editing: Bartosz Dądela, Emilia Majewska, Szymon Gnitecki

Visualization: Natalia Śliwa, Joanna Jasińska, Szymon Janczura, Maciej Borowski

Supervision: Bartosz Dądela, Joanna Jasińska, Eliza Kawalska

Project administration: Bartosz Dądela

All authors have read and agreed with the published version of the manuscript.

Funding Statement

This study did not receive any financial support from outside sources. All research activities were conducted independently of any external funding. No grants, sponsorships, or financial contributions were received that could influence the design, conduct, or outcomes of the review.

Conflict of Interest Statement

The authors declare that there are no conflicts of interest regarding the publication of this review. No financial or personal relationships have influenced the work reported in this manuscript

Informed Consent Statement

Not applicable.

Data Availability Statement

The authors confirm that the data supporting the findings of this study are available within the article's bibliography.

Acknowledgments

Not applicable.

References :

1. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Sep 10;140(11):e596-e646. doi: 10.1161/CIR.0000000000000678. Epub 2019 Mar 17. Erratum in: Circulation. 2019 Sep 10;140(11):e649-e650. doi: 10.1161/CIR.0000000000000725. Erratum in: Circula-

tion. 2020 Jan 28;141(4):e60. doi: 10.1161/CIR.0000000000000755. Erratum in: Circulation. 2020 Apr 21;141(16):e774. doi: 10.1161/CIR.0000000000000771. PMID: 30879355; PMCID: PMC773466

2. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Jun 25;73(24):3168-3209. doi: 10.1016/j.jacc.2018.11.002. Epub 2018 Nov 10. Erratum in: J Am Coll Cardiol. 2019 Jun 25;73(24):3234-3237. doi: 10.1016/j.jacc.2019.05.012. PMID: 30423391.

3. Akira ENDO, A historical perspective on the discovery of statins, Proceedings of the Japan Academy, Series B, 2010, Volume 86, Issue 5, Pages 484-493, Released on J-STAGE May 12, 2010, Online ISSN 1349-2896, Print ISSN 0386-2208, https://doi.org/10.2183/pjab.86.484, https://www.jstage.jst.go.jp/article/pjab/86/5/86_5_484/_article/-char/en

4. François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference, Ian M Graham, Alison Halliday, Ulf Landmesser, Borislava Mihaylova, Terje R Pedersen, Gabriele Riccardi, Dimitrios J Richter, Marc S Sabatine, Marja-Riitta Taskinen, Lale Tokgozoglu, Olov Wiklund, ESC Scientific Document Group , 2019 ESC/EAS Guidelines for the management of dyslipidaemias: *lipid modification to reduce cardiovascular risk*: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS), *European Heart Journal*, Volume 41, Issue 1, 1 January 2020, Pages 111–188, https://doi.org/10.1093/eurheartj/ehz455

5. Banach M, Patti AM, Giglio RV, Cicero AFG, Atanasov AG, Bajraktari G, Bruckert E, Descamps O, Djuric DM, Ezhov M, Fras Z, von Haehling S, Katsiki N, Langlois M, Latkovskis G, Mancini GBJ, Mikhailidis DP, Mitchenko O, Moriarty PM, Muntner P, Nikolic D, Panagiotakos DB, Paragh G, Paulweber B, Pella D, Pitsavos C, Reiner Ž, Rosano GMC, Rosenson RS, Rysz J, Sahebkar A, Serban MC, Vinereanu D, Vrablík M, Watts GF, Wong ND, Rizzo M; International Lipid Expert Panel (ILEP). The Role of Nutraceuticals in Statin Intolerant Patients. J Am Coll Cardiol. 2018 Jul 3;72(1):96-118. doi: 10.1016/j.jacc.2018.04.040. PMID: 29957236

6. Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, Aronow WS, Athyros V, Djuric DM, Ezhov MV, Greenfield RS, Hovingh GK, Kostner K, Serban C, Lighezan D, Fras Z, Moriarty PM, Muntner P, Goudev A, Ceska R, Nicholls SJ, Broncel M, Nikolic D, Pella D, Puri R, Rysz J, Wong ND, Bajnok L, Jones SR, Ray KK, Mikhailidis DP. Statin intolerance - an attempt at a unified definition. Position paper from

an International Lipid Expert Panel. Arch Med Sci. 2015 Mar 16;11(1):1-23. doi: 10.5114/aoms.2015.49807. Epub 2015 Mar 14. PMID: 25861286; PMCID: PMC4379380.

7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994 Nov 19;344(8934):1383-9. PMID: 7968073.

8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002 Jul 6;360(9326):7-22. doi: 10.1016/S0140-6736(02)09327-3. PMID: 12114036.

9. Cholesterol Treatment Trialists' (CTT) Collaboration; Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015 Apr 11;385(9976):1397-405. doi: 10.1016/S0140-6736(14)61368-4. Epub 2015 Jan 9. PMID: 25579834.Collins et al., 2016. Lancet

10. Maciejak A, Leszczynska A, Warchol I, Gora M, Kaminska J, Plochocka D, Wysocka-Kapcinska M, Tulacz D, Siedlecka J, Swiezewska E, Sojka M, Danikiewicz W, Odolczyk N, Szkopinska A, Sygitowicz G, Burzynska B. The effects of statins on the mevalonic acid pathway in recombinant yeast strains expressing human HMG-CoA reductase. BMC Biotechnol. 2013 Aug 30;13:68. doi: 10.1186/1472-6750-13-68. PMID: 24128347; PMCID: PMC3765880.Grundy et al., 2018. J Am Coll Cardiol

11. Schaffer AE, D'Alessio DA, Guyton JR. Extreme elevations of low-density lipoprotein cholesterol with very low carbohydrate, high fat diets. J Clin Lipidol. 2021 May-Jun;15(3):525-526. doi: 10.1016/j.jacl.2021.04.010. Epub 2021 May 7. PMID: 34030981.Libby, 2021. Nature

12. Brown EE, Byrne KH, Davis DM, McClellan R, Leucker T, Jones SR, Martin SS. Incorporation of genetic testing significantly increases the number of individuals diagnosed with familial hypercholesterolemia. J Clin Lipidol. 2020 May-Jun;14(3):331-338. doi: 10.1016/j.jacl.2020.02.006. Epub 2020 Mar 2. PMID: 32220565.Cederberg et al., 2018. Diabetologia

13. Libby, P. The changing landscape of atherosclerosis. *Nature* 592, 524–533 (2021). https://doi.org/10.1038/s41586-021-03392-8

14. Thompson PD, Panza G, Zaleski A, Taylor B. Statin-Associated Side Effects. J Am Coll Cardiol. 2016 May 24;67(20):2395-2410. doi: 10.1016/j.jacc.2016.02.071. PMID: 27199064.

15. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoğlu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB,

Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015 May 1;36(17):1012-22. doi: 10.1093/eurheartj/ehv043. Epub 2015 Feb 18. PMID: 25694464; PMCID: PMC4416140.

16. Sirvent P, Fabre O, Bordenave S, Hillaire-Buys D, Raynaud De Mauverger E, Lacampagne A, Mercier J. Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. Toxicol Appl Pharmacol. 2012 Mar 1;259(2):263-8. doi: 10.1016/j.taap.2012.01.008. Epub 2012 Jan 17. PMID: 22269104.

17. SEARCH Collaborative Group; Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008 Aug 21;359(8):789-99. doi: 10.1056/NEJMoa0801936. Epub 2008 Jul 23. PMID: 18650507.

18. Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, Rysz J, Muntner P, Toth PP, Jones SR, Rizzo M, Kees Hovingh G, Farnier M, Moriarty PM, Bittner VA, Lip GY, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol. 2015 Jan 15;178:111-6. doi: 10.1016/j.ijcard.2014.10.118. Epub 2014 Oct 22. PMID: 25464233.

19. Skarlovnik A, Janić M, Lunder M, Turk M, Šabovič M. Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study. Med Sci Monit. 2014 Nov 6;20:2183-8. doi: 10.12659/MSM.890777. PMID: 25375075; PMCID: PMC4226312.

20. Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng D, Pearson GJ, Pope J, Tashakkor AY. Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). Can J Cardiol. 2016 Jul;32(7 Suppl):S35-65. doi: 10.1016/j.cjca.2016.01.003. Epub 2016 Jan 14. PMID: 27342697.

21. Kosoglou T, Statkevich P, Yang B, Suresh R, Zhu Y, Boutros T, Maxwell SE, Tiessen R, Cutler DL. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin. 2004 Aug;20(8):1185-95. doi: 10.1185/030079904125004213. PMID: 15324521.

22. Michos ED, Blaha MJ, Blumenthal RS. Use of the Coronary Artery Calcium Score in Discussion of Initiation of Statin Therapy in Primary Prevention. Mayo Clin Proc. 2017 Dec;92(12):1831-1841. doi: 10.1016/j.mayocp.2017.10.001. Epub 2017 Nov 3. PMID: 29108840.

23. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group; Armitage J, Bowman L, Wallendszus K, Bulbulia R,

Rahimi K, Haynes R, Parish S, Peto R, Collins R. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010 Nov 13;376(9753):1658-69. doi: 10.1016/S0140-6736(10)60310-8. Epub 2010 Nov 8. Erratum in: Lancet. 2011 Jan 8;377(9760):126. PMID: 21067805; PMCID: PMC2988223.

24. Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, Chipkin S, Pescatello LS, Simpson K, White CM, Thompson PD. Effect of statins on skeletal muscle function. Circulation. 2013 Jan 1;127(1):96-103. doi: 10.1161/CIRCULATIONAHA.112.136101. Epub 2012 Nov 26. PMID: 23183941; PMCID: PMC4450764.

25. Wanner C, Tonelli M; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014 Jun;85(6):1303-9. doi: 10.1038/ki.2014.31. Epub 2014 Feb 19. PMID: 24552851.

26. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17. PMID: 28304224.

27. Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, Kelly S, Stroes ESG. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. J Am Heart Assoc. 2019 Apr 2;8(7):e011662. doi: 10.1161/JAHA.118.011662. PMID: 30922146; PMCID: PMC6509724.

28. Stone NJ, Robinson JG, Lichtenstein AH, Goff DC Jr, Lloyd-Jones DM, Smith SC Jr, Blum C, Schwartz JS; 2013 ACC/AHA Cholesterol Guideline Panel. Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. Ann Intern Med. 2014 Mar 4;160(5):339-43. doi: 10.7326/M14-0126. PMID: 24474185.

29. Björnsson ES. Hepatotoxicity of statins and other lipid-lowering agents. Liver Int. 2017 Feb;37(2):173-178. doi: 10.1111/liv.13308. Epub 2016 Nov 27. PMID: 27860156.

30. Bhardwaj SS, Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis. 2007 Aug;11(3):597-613, vii. doi: 10.1016/j.cld.2007.06.010. PMID: 17723922; PMCID: PMC2048990.

31. Schirris TJ, Renkema GH, Ritschel T, Voermans NC, Bilos A, van Engelen BG, Brandt U, Koopman WJ, Beyrath JD, Rodenburg RJ, Willems PH, Smeitink JA, Russel FG. Statin-Induced Myopathy Is Associated with Mitochondrial Complex III Inhibition. Cell Metab. 2015 Sep 1;22(3):399-407. doi: 10.1016/j.cmet.2015.08.002. PMID: 26331605.

32. Qu H, Guo M, Chai H, Wang WT, Gao ZY, Shi DZ. Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2018 Oct 2;7(19):e009835. doi: 10.1161/JAHA.118.009835. PMID: 30371340; PMCID: PMC6404871.
33. Deichmann R, Lavie C, Andrews S. Coenzyme q10 and statin-induced mitochondrial dysfunction. Ochsner J. 2010 Spring;10(1):16-21. PMID: 21603349; PMCID: PMC3096178.
34. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007 Jun 12;49(23):2231-7. doi: 10.1016/j.jacc.2007.02.049. PMID: 17560286.
35. Nassir F, Rector RS, Hammoud GM, Ibdah JA. Pathogenesis and Prevention of Hepatic Steatosis. Gastroenterol Hepatol (N Y). 2015 Mar;11(3):167-75. PMID: 27099587; PMCID: PMC4836586.
36. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006 Apr 17;97(8A):52C-60C. doi: 10.1016/j.amjcard.2005.12.010. Epub 2006 Feb 3. PMID: 16581329.
37. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther. 2005 Dec;19(6):403-14. doi: 10.1007/s10557-005-5686-z. PMID: 16453090.
38. Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2013 Apr 25;10(7):796-803. doi: 10.7150/ijms.6048. PMID: 23794943; PMCID: PMC3689877.
39. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005 Feb;19(1):117-25. doi: 10.1111/j.1472-8206.2004.00299.x. PMID: 15660968.
40. Sigler MA, Congdon L, Edwards KL. An Evidence-Based Review of Statin Use in Patients With Nonalcoholic Fatty Liver Disease. Clin Med Insights Gastroenterol. 2018 Jul 10;11:1179552218787502. doi: 10.1177/1179552218787502. PMID: 30013416; PMCID: PMC6043943.
41. Alexander W. European Association for the Study of the Liver The International Liver Congress 2019. P T. 2019 Jun;44(6):365-369. PMID: 31160873; PMCID: PMC6534177.
42. SEARCH Collaborative Group; Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008 Aug 21;359(8):789-99. doi: 10.1056/NEJMoa0801936. Epub 2008 Jul 23. PMID: 18650507.
43. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K,

Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3. PMID: 26039521.

44. Writing Committee; Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, DePalma SM, Minissian MB, Orringer CE, Smith SC Jr, Waring AA, Wilkins JT. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022 Oct 4;80(14):1366-1418. doi: 10.1016/j.jacc.2022.07.006. Epub 2022 Aug 25. Erratum in: J Am Coll Cardiol. 2023 Jan 3;81(1):104. doi: 10.1016/j.jacc.2022.11.016. PMID: 36031461.

45. Averbukh LD, Turshudzhyan A, Wu DC, Wu GY. Statin-induced Liver Injury Patterns: A Clinical Review. J Clin Transl Hepatol. 2022 Jun 28;10(3):543-552. doi: 10.14218/JCTH.2021.00271. Epub 2022 Jan 10. PMID: 35836753; PMCID: PMC9240239.

46. Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.

47. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019 Feb 2;393(10170):407-415. doi: 10.1016/S0140-6736(18)31942-1. PMID: 30712900; PMCID: PMC6429627.

48. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9. PMID: 18997196.

49. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010 Feb 27;375(9716):735-42. doi: 10.1016/S0140-6736(09)61965-6. Epub 2010 Feb 16. PMID: 20167359.

50. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011 Jun 22;305(24):2556-64. doi: 10.1001/jama.2011.860. PMID: 21693744.

51. Koh KK, Quon MJ, Sakuma I, Han SH, Choi H, Lee K, Shin EK. Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients. Int J Cardiol. 2013 Jun 20;166(2):509-15. doi: 10.1016/j.ijcard.2011.11.028. Epub 2011 Dec 26. PMID: 22204857.

52. Laybutt DR, Preston AM, Akerfeldt MC, Kench JG, Busch AK, Biankin AV, Biden TJ. Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes. Diabetologia. 2007 Apr;50(4):752-63. doi: 10.1007/s00125-006-0590-z. Epub 2007 Feb 1. PMID: 17268797.

53. Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JE, Shah T, Sofat R, Stender S, Johnson PC, Scott RA, Leusink M, Verweij N, Sharp SJ, Guo Y, Giambartolomei C, Chung C, Peasey A, Amuzu A, Li K, Palmen J, Howard P, Cooper JA, Drenos F, Li YR, Lowe G, Gallacher J, Stewart MC, Tzoulaki I, Buxbaum SG, van der A DL, Forouhi NG, Onland-Moret NC, van der Schouw YT, Schnabel RB, Hubacek JA, Kubinova R, Baceviciene M, Tamosiunas A, Pajak A, Topor-Madry R, Stepaniak U, Malyutina S, Baldassarre D, Sennblad B, Tremoli E, de Faire U, Veglia F, Ford I, Jukema JW, Westendorp RG, de Borst GJ, de Jong PA, Algra A, Spiering W, Maitland-van der Zee AH, Klungel OH, de Boer A, Doevendans PA, Eaton CB, Robinson JG, Duggan D; DIAGRAM Consortium; MAGIC Consortium; InterAct Consortium; Kjekshus J, Downs JR, Gotto AM, Keech AC, Marchioli R, Tognoni G, Sever PS, Poulter NR, Waters DD, Pedersen TR, Amarenco P, Nakamura H, McMurray JJ, Lewsey JD, Chasman DI, Ridker PM, Maggioni AP, Tavazzi L, Ray KK, Seshasai SR, Manson JE, Price JF, Whincup PH, Morris RW, Lawlor DA, Smith GD, Ben-Shlomo Y, Schreiner PJ, Fornage M, Siscovick DS, Cushman M, Kumari M, Wareham NJ, Verschuren WM, Redline S, Patel SR, Whittaker JC, Hamsten A, Delaney JA, Dale C, Gaunt TR, Wong A, Kuh D, Hardy R, Kathiresan S, Castillo BA, van der Harst P, Brunner EJ, Tybjaerg-Hansen A, Marmot MG, Krauss RM, Tsai M, Coresh J, Hoogeveen RC, Psaty BM, Lange LA, Hakonarson H, Dudbridge F, Humphries SE, Talmud PJ, Kivimäki M, Timpson NJ, Langenberg C, Asselbergs FW, Voevoda M, Bobak M, Pikhart H, Wilson JG, Reiner AP, Keating BJ, Hingorani AD, Sattar N. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2015 Jan 24;385(9965):351-61. doi: 10.1016/S0140-6736(14)61183-1. Epub 2014 Sep 24. PMID: 25262344; PMCID: PMC4322187.

54. Cederberg H, Stančáková A, Yaluri N, Modi S, Kuusisto J, Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia. 2015

May;58(5):1109-17. doi: 10.1007/s00125-015-3528-5. Epub 2015 Mar 10. PMID: 25754552.

55. Navarese EP, Andreotti F, Schulze V, Kołodziejczak M, Buffon A, Brouwer M, Costa F, Kowalewski M, Parati G, Lip GY, Kelm M, Valgimigli M. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ. 2015 Apr 16;350:h1618. doi: 10.1136/bmj.h1618. Erratum in: BMJ. 2016 Oct 17;355:i5600. doi: 10.1136/bmj.i5600. PMID: 25883067; PMCID: PMC4410620.

56. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 Jan 1;45(Suppl 1):S125-S143. doi: 10.2337/dc22-S009. PMID: 34964831.

57. Schultz BG, Patten DK, Berlau DJ. The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. Transl Neurodegener. 2018 Feb 27;7:5. doi: 10.1186/s40035-018-0110-3. PMID: 29507718; PMCID: PMC5830056

58. Rojas-Fernandez CH, Cameron JC. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother. 2012 Apr;46(4):549-57. doi: 10.1345/aph.1Q620. Epub 2012 Apr 3. PMID: 22474137.

59. Pfrieger FW, Ungerer N. Cholesterol metabolism in neurons and astrocytes. Prog Lipid Res. 2011 Oct;50(4):357-71. doi: 10.1016/j.plipres.2011.06.002. Epub 2011 Jul 1. PMID: 21741992.

60. Johnson-Anuna LN, Eckert GP, Keller JH, Igbavboa U, Franke C, Fechner T, Schubert-Zsilavecz M, Karas M, Müller WE, Wood WG. Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharmacol Exp Ther. 2005 Feb;312(2):786-93. doi: 10.1124/jpet.104.075028. Epub 2004 Sep 9. PMID: 15358814.

61. Mollazadeh H, Tavana E, Fanni G, Bo S, Banach M, Pirro M, von Haehling S, Jamialahmadi T, Sahebkar A. Effects of statins on mitochondrial pathways. J Cachexia Sarcopenia Muscle. 2021 Apr;12(2):237-251. doi: 10.1002/jcsm.12654. Epub 2021 Jan 29. PMID: 33511728; PMCID: PMC8061391.

62. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002 Nov 23;360(9346):1623-30. doi: 10.1016/s0140-6736(02)11600-x. PMID: 12457784.

63. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003 Jul;23(7):871-80. doi: 10.1592/phco.23.7.871.32720. PMID: 1288510

64. Healy D, Morgan R, Chinnaswamy S. Transient global amnesia associated with statin intake. BMJ Case Rep. 2009;2009:bcr06.2008.0033. doi: 10.1136/bcr.06.2008.0033. Epub 2009 Feb 26. PMID: 21686951; PMCID: PMC3027897.

65. Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc. 2013 Nov;88(11):1213-21. doi: 10.1016/j.mayocp.2013.07.013. Epub 2013 Oct 1. PMID: 24095248.

66. Cheeley MK, Saseen JJ, Agarwala A, Ravilla S, Ciffone N, Jacobson TA, Dixon DL, Maki KC. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol. 2022 Jul-Aug;16(4):361-375. doi: 10.1016/j.jacl.2022.05.068. Epub 2022 Jun 9. PMID: 35718660.

67. Rundek T, Naini A, Sacco R, Coates K, DiMauro S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol. 2004 Jun;61(6):889-92. doi: 10.1001/archneur.61.6.889. PMID: 15210526.

68. Martínez-Lapiscina EH, Clavero P, Toledo E, Estruch R, Salas-Salvadó J, San Julián B, Sanchez-Tainta A, Ros E, Valls-Pedret C, Martinez-Gonzalez MÁ. Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised trial. J Neurol Neurosurg Psychiatry. 2013 Dec;84(12):1318-25. doi: 10.1136/jnnp-2012-304792. Epub 2013 May 13. PMID: 23670794.

69. Mangravite LM, Engelhardt BE, Medina MW, Smith JD, Brown CD, Chasman DI, Mecham BH, Howie B, Shim H, Naidoo D, Feng Q, Rieder MJ, Chen YD, Rotter JI, Ridker PM, Hopewell JC, Parish S, Armitage J, Collins R, Wilke RA, Nickerson DA, Stephens M, Krauss RM. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature. 2013 Oct 17;502(7471):377-80. doi: 10.1038/nature12508. Epub 2013 Aug 28. PMID: 23995691; PMCID: PMC3933266.

70. Licher S, Ahmad S, Karamujić-Čomić H, Voortman T, Leening MJG, Ikram MA, Ikram MK. Genetic predisposition, modifiable-risk-factor profile and long-term dementia risk in the general population. Nat Med. 2019 Sep;25(9):1364-1369. doi: 10.1038/s41591-019-0547-7. Epub 2019 Aug 26. PMID: 31451782; PMCID: PMC6739225.

71. Cholesterol Treatment Trialists' (CTT) Collaborators; Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012 Aug 11;380(9841):581-90. doi: 10.1016/S0140-6736(12)60367-5. Epub 2012 May 17. PMID: 22607822; PMCID: PMC3437972.

72. Cholesterol Treatment Trialists' (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5. Epub 2010 Nov 8. PMID: 21067804; PMCID: PMC2988224.

73. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-

Charvet L. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012 Apr 17;125(15):1905-19. doi: 10.1161/CIRCULATIONAHA.111.066589. PMID: 22508840; PMCID: PMC4159082.
74. Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Am Heart J. 2019 Apr;210:18-28. doi: 10.1016/j.ahj.2018.12.007. Epub 2019 Jan 10. PMID: 30716508.
75. Howard, J, Wood, F, Finegold, J. et al. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment. JACC. 2021 Sep, 78 (12) 1210–1222.https://doi.org/10.1016/j.jacc.2021.07.022
76. Brunetti L, Hermes-DeSantis ER. The Role of Colesevelam Hydrochloride in Hypercholesterolemia and Type 2 Diabetes Mellitus. Annals of Pharmacotherapy. 2010;44(7-8):1196-1206. doi:10.1345/aph.1M728
77. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7. PMID: 30403574.
78. Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, Lalwani ND, Patel PM, Zhao X, Duell PB. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. JAMA. 2019 Nov 12;322(18):1780-1788. doi: 10.1001/jama.2019.16585. Erratum in: JAMA. 2020 Jan 21;323(3):282. doi: 10.1001/jama.2019.20661. PMID: 31714986; PMCID: PMC6865290.
79. Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, Averna MR, Sirtori CR, Shah PK, Gaudet D, Stefanutti C, Vigna GB, Du Plessis AM, Propert KJ, Sasiela WJ, Bloedon LT, Rader DJ; Phase 3 HoFH Lomitapide Study investigators. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013 Jan 5;381(9860):40-6. doi: 10.1016/S0140-6736(12)61731-0. Epub 2012 Nov 2. PMID: 23122768; PMCID: PMC4587657.
80. Estruch R, Martínez-González MA, Corella D, Salas-Salvadó J, Fitó M, Chiva-Blanch G, Fiol M, Gómez-Gracia E, Arós F, Lapetra J, Serra-Majem L, Pintó X, Buil-Cosiales P, Sorlí JV, Muñoz MA, Basora-Gallisá J, Lamuela-Raventós RM, Serra-Mir M, Ros E; PREDIMED Study Investigators. Effect of a high-fat Mediterranean diet on bodyweight and waist circumference: a prespecified secondary outcomes analysis of the PREDIMED randomised controlled trial. Lancet Diabetes Endocrinol. 2019 May;7(5):e6-e17. doi: 10.1016/S2213-8587(19)30074-9. PMID: 31003626.
81. Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, Ali S, Banerjee P, Chan KC, Gipe DA, Khilla N, Pordy R, Weinreich DM, Yancopoulos GD, Zhang Y, Gaudet D; ELIPSE HoFH Investigators. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020 Aug 20;383(8):711-720. doi: 10.1056/NEJMoa2004215. PMID: 32813947.
82. Libby P, Aikawa M. Mechanisms of plaque stabilization with statins. Am J Cardiol. 2003 Feb 20;91(4A):4B-8B. doi: 10.1016/s0002-9149(02)03267-8. PMID: 12615292.

83. Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, Turchin A. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013 Apr 2;158(7):526-34. doi: 10.7326/0003-4819-158-7-201304020-00004. PMID: 23546564; PMCID: PMC3692286.
84. Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther. 1998 Mar;63(3):332-41. doi: 10.1016/S0009-9236(98)90165-5. PMID: 9542477.
85. Turner, R. M., & Pirmohamed, M. (2020). Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components. *Journal of Clinical Medicine*, *9*(1), 22. https://doi.org/10.3390/jcm9010022